Celularity Inc Dossier
Qualitative Analysis
Business overview
Celularity Inc. (Nasdaq: CELU) is a clinical-stage, longevity-focused regenerative and cellular medicine company. The company specializes in developing and manufacturing off-the-shelf allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta's unique biology, immunologic properties, and scalable availability to target fundamental mechanisms of aging, age-related diseases, cancer, and infectious diseases. Its operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. The company operates a state-of-the-art 147,215 square foot manufacturing facility in Florham Park, New Jersey.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the divestiture of its biomaterials business, Celularity is concentrating its resources, scientific expertise, and manufacturing capabilities on its core longevity and cell therapy platforms, specifically prioritizing its mature allogeneic cell therapy asset, cenplacel-L.
Expected impact: Streamlines the operating structure, reduces operating expenses, and focuses capital on high-value clinical and longevity-focused therapeutic programs.
Expanding physician access and patient adoption of cenplacel-L, particularly in jurisdictions with supportive regulatory frameworks such as Florida, utilizing the newly appointed Chief Commercial Officer to build a disciplined and scalable commercial model.
Expected impact: Drives near-term commercial revenue growth from cell therapies and establishes a strong clinical footprint.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Monetizes Celularity's non-core commercial biomaterials portfolio, allowing the company to retire debt, reduce liabilities, and focus entirely on cellular therapies.
Terms: Aggregate consideration of $13.3 million at closing (consisting of $8.3 million in cash and a $5.0 million convertible promissory note), plus potential future milestone payments of up to $20.0 million and royalties on certain development-stage products.
Establishes an initial clinical channel and patient selection framework for the investigational use of cenplacel-L under Florida's regenerative medicine statutes.
Terms: Not explicitly disclosed.
Positions Celularity as the exclusive supplier of placenta-derived stem cells for Genting's state-of-the-art Fontaine Vitale wellness facility in Bali, Indonesia, expanding Celularity's reach into the Asia-Pacific market.
Terms: Celularity will manufacture and export stem cells from its US facility, with plans to transition to onsite manufacturing under Celularity's technical supervision.
Sublicenses Celularity's ophthalmic biologic solutions portfolio (including the BIOVANCE franchise) to DefEYE to accelerate commercialization in the ophthalmic space.
Terms: Celularity invested in DefEYE as part of DefEYE's $12.0 million Series Seed funding round and granted an exclusive sublicense for its ophthalmic biologics portfolio.